Cannabis
Oppenheimer Continues To Grow Its Global Consumer Investment Banking Group With Appointment Of Jean-Marie Gianni As Managing Director
Oppenheimer& Co. Inc., a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced the continued build-out of its Global Consumer Investment Banking Group with the appointment of Jean-Marie Gianni as a Managing Director, based in New York. Mr. Gianni will report to Emmanuel Durand, Global Head of Consumer Investment Banking, and Rita Dagdelen-Keskinyan, Head of North America Consumer Investment Banking.
Mrs. Dagdelen-Keskinyan said, “We are very pleased and excited to welcome Jean-Marie to our Global Consumer Investment Banking team. Jean-Marie’s respected industry insight, experience and well-established relationships in the Health & Beauty / Personal Care consumer segments will complement and enhance the growth of our broader Consumer coverage into optimal adjacencies, including health and wellness-focused food & beverage and cannabis / CBD coverage in North America. Jean-Marie will also help us further our penetration in these new segments on a cross-border basis, specifically in the UK and Europe.”
Along with the addition of Managing Director James Murray to Oppenheimer’s Global Consumer Investment Banking team in London last November, today’s announcement demonstrates the firm’s ongoing commitment to building its Consumer group through selective hiring of senior banking talent. Mr. Gianni and the other members of the Group will work in concert with Oppenheimer’s leading middle-market M&A and equity capital markets capabilities while also leveraging the strengths of the firm’s equity research platform to drive continued growth in the consumer segment.
Mr. Gianni joins Oppenheimer with over 15 years of experience in providing strategic advice to an extensive range of clients in both the Health & Beauty and Personal Care markets. He will be primarily focused on the North American market while also working closely with Oppenheimer’s Consumer Investment Banking team in London to expand Oppenheimer’s coverage in this segment.
Mr. Gianni started his investment banking career at Lazard in Paris and New York and continued subsequently at Moelis & Co., where he was a senior member of the firm’s Health & Beauty and Personal Care advisory practice. He has advised on over $50 billion worth of closed transactions, representing private and public companies, entrepreneurs and private equity clients.
Oppenheimer’s ongoing, focused expansion of its senior investment banking leadership and expertise across key industries and sectors, coupled with continual investment in its leading equity research capabilities, has been one of the primary drivers of the firm’s record-setting investment banking results over the past two years. Full-year investment banking revenue of $222.3 million for 2020 increased 76% over 2019, while the division’s revenue increased 219% through the first half of 2021 versus the same period in 2020, to $229.2 million.
Mrs. Dagdelen-Keskinyan concluded, “Oppenheimer is committed to the continued expansion of its global investment banking capabilities and to servicing the needs of its corporate and private equity clients by providing seamless coverage across the globe. We welcome Jean-Marie to the team, and we look forward to driving continued success in the years ahead.”
Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), and its affiliates provide a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, local governments, businesses and institutions. For more information, please visit www.oppenheimer.com.
Cannabis
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth
Cannabis
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
Cannabis
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis2 weeks ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 weeks ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
Cannabis2 weeks ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
-
Cannabis7 days ago
IM Cannabis Reports First Quarter Financial Results
-
Cannabis6 days ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Innocan5 days ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis2 days ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa